Monoclonal antibodies for the prevention of migraine

References

• Jensen R, Stovner LJ. Epidemiology and comorbidity of headache. Lancet Neurol. 2008;7(4):354–361.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• Van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21(5):649–678.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–196.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol. 2019. DOI:10.1038/s41582-019-0216-y
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.
   PubMed Web of Science ®Google Scholar
• Ashina M, Hansen JM, BO ÁD, et al. Human models of migraine — short-term pain for long-term gain. Nat Rev Neurol. 2017;13:713.
   PubMed Web of Science ®Google Scholar
• Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia. 1995;15(5):384–390.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48–56.
   PubMed Web of Science ®Google Scholar
• Ramón C, Cernuda-Morollón E, Pascual J. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Curr Opin Neurol. 2017;30(3):281–286.
   PubMed Web of Science ®Google Scholar
• Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129(3):420–423.
   Web of Science ®Google Scholar
• Olesen J, Diener H-C, Husstedt IW, et al. Calcitonin gene–related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–1110.
   PubMed Web of Science ®Google Scholar
• Urits I, Jones MR, Gress K, et al. CGRP antagonists for the treatment of chronic migraines: a comprehensive review. Curr Pain Headache Rep. 2019;23(5):29.
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28: 555–567. [epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S. monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28(5):389–399.
   PubMed Web of Science ®Google Scholar
• Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-cgrp monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017;6(6):534–547.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–1107.
   PubMed Web of Science ®Google Scholar
• Baker B, Schaeffler B, Cady R, et al. Rational design of a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, ALD403 (eptinezumab), intended for the prevention of migraine. Poster presented at the American Academy of Neurology (AAN) 2017 Annual Meeting, Boston, MA.
   Google Scholar
• Cohen-Barak O, Weiss S, Rasamoelisolo M, et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia. 2018;38(13):1960–1971.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Prescribing information - Fremanezumab. [cited 2019 Jun 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf
   Google Scholar
• Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol. 2008;155(7):1093–1103.
   PubMed Web of Science ®Google Scholar
• Monteith D, Collins EC, Vandermeulen C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (Galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:740–740.
   PubMed Web of Science ®Google Scholar
• Shi L, Lehto SG, Zhu DXD, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223–231.
   PubMed Web of Science ®Google Scholar
• Vu T, Ma P, Chen JS, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects. Pharm Res. 2017;34(9):1784–1795.
   PubMed Web of Science ®Google Scholar
• de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018;103(5):815–825.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Prescribing information - Erenumab. [cited 2019 Jun 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf
   Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187–193.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999–2008.
   PubMed Web of Science ®Google Scholar
• Saper JR, Lipton RB, Kudrow DB, et al. A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab in frequent episodic migraine prevention: primary results of the PROMISE-1 (prevention of migraine via intravenous eptinezumab safety and efficacy–1) trial. Poster presented at the International Headache Congress, Vancouver, Canada; September 2017.
   Google Scholar
• Alder Biopharmaceuticals. Alder BioPharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine. [cited 2019 Jun 12]. Available from: https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticals-announces-positive-eptinezumab-phase-3
   Google Scholar
• Bagley CL, Rendas-Baum R, Maglinte GA, et al. Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache. 2012;52(3):409–421.
   PubMed Web of Science ®Google Scholar
• Speck RM, Shalhoub H, Wyrwich KW, et al. Psychometric validation of the role function restrictive domain of the migraine specific quality-of-life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. Headache. 2019;59(5):756–774.
   PubMed Web of Science ®Google Scholar
• Dell’Agnello G, Tockhorn-Heidenreich G, Zhang Q, et al. Efficacy of galcanezumab in patients who failed prior preventive treatments for migraine: results from EVOLVE-1, EVOLVE-2, and REGAIN studies. Presented at: 12th European Headache Federation Congress (EHF); 2018 Sep 28–30; Florence, Italy.
   Google Scholar
• ClinicalTrials.gov. A study of galcanezumab (LY2951742) in adults with treatment-resistant migraine (CONQUER). [cited 2019 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03559257
   Google Scholar
• Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188–188.
   PubMed Web of Science ®Google Scholar
• Schwedt T, Reuter U, Tepper S, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018;19(1):92.
   PubMedGoogle Scholar
• Goadsby PJ, Paemeleire K, Broessner G, et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2019;39(7):817–826.
   Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Long-term efficacy and safety of erenumab: results from 64 weeks of the LIBERTY study. Presented at: 13th European Headache Federation Congress (EHF); May 30-June 02; Athens, Greece.
   Google Scholar
• Silberstein S, Spierings ELH, Berman G, et al. Eptinezumab reduced migraine frequency and triptan/ergotamine use over weeks 1–12, and improved HIT‐6 scores at months 1 and 3: results from the phase 3 PROMISE‐2 trial in chronic migraine. [cited 2019 Jun 12]. Available from: https://investor.alderbio.com/static-files/f6ddad4a-87d0-460b-9807-d1a8192a0b5a
   Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Gandhi SK, Fitzgerald T, et al. The positive impact of fremanezumab on work productivity and activity impairment in patients with chronic migraine (S32.007). Neurology. 2018;90(15Supplement):S32.007.
   PubMedGoogle Scholar
• Cohen JM, Yeung PP, Aycardi E, et al. Efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to moderately severe depression (P4.097). Neurology. 2018;90(15Supplement):P4.097.
   Google Scholar
• Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018;38(10):1611–1621.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Ashina M, Brandes JL, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology. 2019. epub ahead of print. DOI:10.1212/WNL.0000000000007497.
   Google Scholar
• Lipton RB, Tepper SJ, Reuter U, et al. Erenumab in chronic migraine. Patient-reported outcomes in a randomized double-blind study. Neurology. 2019;92(19):e2250–e2260.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to assess the long-term safety and efficacy of erenumab (AMG 334) in chronic migraine prevention. [cited 2019 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT02174861
   Google Scholar
• Alder BioPharmaceuticals. U.S. Food and Drug Administration accepts biologics license application for eptinezumab. [cited 2019 Jun 12]. Available from: https://www.globenewswire.com/news-release/2019/04/22/1807504/0/en/U-S-Food-and-Drug-Administration-Accepts-Biologics-License-Application-for-Eptinezumab.html
   Google Scholar
• Tepper SJ. Anti-calcitonin gene-related peptide (cgrp) therapies: update on a previous review after the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. Headache. 2018;58(S3):276–290.
   PubMedGoogle Scholar
• Lamb YN. Galcanezumab: first Global Approval. Drugs. 2018;78(16):1769–1775.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Prescribing information - Galcanezumab. [cited 2019 Jun 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf
   Google Scholar
• Markham A. Erenumab: first Global Approval. Drugs. 2018;78(11):1157–1161.
   PubMed Web of Science ®Google Scholar
• Tepper SJ. History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment. Headache. 2018;58(S3):238–275.
   PubMedGoogle Scholar
• GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Head-to-head study of erenumab against topiramate in patients with episodic migraine (HER-MES). [cited 2019 Jun 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT03828539
   Google Scholar
• Novartis. Novartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN. [cited 2019 Jun 12]. Available from: https://novartis.gcs-web.com/Novartis-to-highlight-extensive-long-term-safety-and-efficacy-data-of-Aimovig-across-the-spectrum-of-migraine-at-AAN
   Google Scholar
• Lipton RB, Brennan A, Palmer S, et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ. 2018;21(7):666–675.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Broessner G, Buse DC, et al. Efficacy of erenumab for the treatment of patients with episodic migraine with depression and/or anxiety. Poster 103. 68th American Academy of Neurology meeting; 2018 Apr 25; Los Angeles, CA. (abstract).
   Google Scholar
• Barbanti P, Egeo G. Pharmacological trials in migraine: it’s time to reappraise where the headache is and what the pain is like. Headache. 2015;55(3):439–441.
   PubMed Web of Science ®Google Scholar
• Hargreaves R, Olesen J. Calcitonin gene-related peptide modulators – the history and renaissance of a new migraine drug class. Headache. 2019;59(6):951–970.
   PubMed Web of Science ®Google Scholar
• Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004;84(3):903–934.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache. CNS Drugs. 2001;15(10):745–753.
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators. Expert Opin Inv Drugs. 2001;10(6):1131–1138.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Meijer J, Villalón CM, et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37(9):779–788.
   PubMed Web of Science ®Google Scholar
• Depre C, Antalik L, Starling A, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018;58(5):715–723.
   PubMed Web of Science ®Google Scholar
• Tepper SJ, Pascual J, Reuter U, et al. Analysis of blood pressure following short-term and long-term treatment with erenumab. Poster 105. 68th American Academy of Neurology meeting; 2018 April 25; Los Angeles, CA. (abstract).
   Google Scholar
• Walter S, Bigal ME. TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine. Curr Pain Headache Rep. 2015;19(3):6.
   PubMed Web of Science ®Google Scholar
• Kaiser EA, Rea BJ, Kuburas A, et al. Anti-CGRP antibodies block CGRP-induced diarrhea in mice. Neuropeptides. 2017;64:95–99.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53(8):1230–1244.
   PubMed Web of Science ®Google Scholar
• Schneider J, Jehle EC, Starlinger MJ, et al. Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn’s disease. Neurogastroenterol Motil. 2001;13(3):255–264.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Juul R. Peptidergic innervation of the cerebral circulation. Role in subarachnoid hemorrhage in man. Neurosurg Rev. 1990;13:265–272.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. Correction to: european headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):58.
   PubMedGoogle Scholar
• Raffaelli B, Mussetto V, Israel H, et al. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019;20(1):66.
   PubMedGoogle Scholar